Jove
Visualize
Contact Us

Related Experiment Videos

Decrease of left ventricular mass is a clinically valuable intermediate end-point of antihypertensive treatment

E Agabiti-Rosei1

  • 1Semiotica and Metodologia Medica, University of Brescia, Italy. agabiti@master.cci.unibs.it

Blood Pressure. Supplement
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond gout: uric acid and cardiovascular diseases.

Current medical research and opinion·2013
Same author

Echocardiography in clinical practice: the burden of arterial hypertension. A multicenter Italian survey.

Journal of human hypertension·2009
Same author

Macro and microvasculature in hypertension: therapeutic aspects.

Journal of human hypertension·2008
Same author

Maternal cardiovascular function in pregnancies complicated by intrauterine growth restriction.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2007
Same author

Genetic mutation screening in an italian cohort of nonsyndromic pheochromocytoma/paraganglioma patients.

Annals of the New York Academy of Sciences·2006
Same author

[A new strategy in the treatment of hypertension and its lesions on the target organs].

Presse medicale (Paris, France : 1983)·2004
Same journal

Efficacy and safety of early versus late titration of fixed-dose irbesartan/hydrochlorothiazide: ACTUAL study.

Blood pressure. Supplement·2012
Same journal

Efficacy and safety of valsartan in hypertensive Taiwanese patients: post-marketing surveillance study.

Blood pressure. Supplement·2012
Same journal

Effect of fixed dose combinations of metoprolol and amlodipine in essential hypertension: MARS--a randomized controlled trial.

Blood pressure. Supplement·2012
Same journal

Post-registration studies for the evaluation of antihypertensive drugs.

Blood pressure. Supplement·2012
Same journal

Effects of candesartan versus amlodipine on home-measured blood pressure, QT dispersion and left ventricular hypertrophy in high-risk hypertensive patients.

Blood pressure. Supplement·2011
Same journal

Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension.

Blood pressure. Supplement·2010
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Left ventricular hypertrophy (LVH) in hypertension is a poor prognostic sign linked to increased cardiovascular events. Reducing LVH may improve outcomes in hypertensive patients.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Clinical Medicine

Background:

  • Left ventricular hypertrophy (LVH) in hypertensive patients is a significant predictor of cardiovascular morbidity and mortality.
  • LVH is associated with adverse pathophysiological changes, including impaired cardiac function and increased arrhythmia risk.

Purpose of the Study:

  • To highlight the prognostic implications of LVH in hypertension.
  • To discuss the pathophysiological mechanisms linking LVH to cardiovascular risk.
  • To emphasize the therapeutic goal of LVH regression for improved patient outcomes.

Main Methods:

  • Clinical recognition of LVH through electrocardiography and echocardiography.
  • Review of pathophysiological changes associated with hypertensive LVH.

Related Experiment Videos

  • Analysis of the relationship between LVH and cardiovascular risk factors.

    • Main Results:

    • LVH independently predicts cardiovascular morbidity and mortality in hypertensive individuals.
    • Pathophysiological changes include diastolic dysfunction, reduced coronary flow reserve, arrhythmias, and altered autonomic activity.
    • These factors contribute to the increased cardiovascular risk observed in patients with LVH.

    Conclusions:

    • Regression of LVH should be a primary treatment objective in hypertensive patients.
    • Achieving LVH regression may lead to improved cardiovascular prognosis.
    • Understanding the mechanisms of LVH is crucial for effective hypertension management.